Related Experiment Videos
A guide to therapeutic decision-making in patients with non-ST-segment elevation acute coronary syndromes
1Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA. topole@ccf.org
Insights
Inflammation drives acute ischemic heart disease, with elevated inflammatory markers and platelet mediators indicating risk. Treatment decisions for coronary revascularization involve balancing invasive versus conservative strategies based on patient risk stratification.
Area of Science:
- Cardiology
- Immunology
- Pharmacology
Background:
- Acute ischemic heart disease is increasingly recognized as having an inflammatory origin.
- Inflammation in coronary arteries releases cytokines like tissue factor, promoting thrombosis.
- Elevated serum inflammatory markers, including high-sensitivity C-reactive protein (CRP) and interleukin-6, are common in acute coronary syndrome.
Purpose of the Study:
- To explore the role of inflammation in acute ischemic heart disease.
- To discuss the significance of inflammatory biomarkers and platelet mediators in pathophysiology.
- To review current therapeutic strategies and decision-making in coronary revascularization.
Main Methods:
- Review of recent clinical trial evidence and scientific literature.
- Analysis of the role of inflammatory cytokines and platelet-derived mediators.
- Evaluation of diagnostic biomarkers such as CRP and troponin.
- Assessment of therapeutic armamentarium including antithrombotics and revascularization strategies.
Main Results:
- Inflammation is a key factor in acute ischemic heart disease, with elevated inflammatory markers predicting mortality risk.
- Platelets contribute significantly to the inflammatory cascade through released mediators and messenger RNA.
- Biomarkers like CRP and troponin offer insights into disease pathophysiology.
- New drug classes and treatment strategies, including invasive versus conservative management, are available.
Conclusions:
- Inflammation plays a critical role in acute ischemic heart disease.
- Biomarkers provide valuable prognostic information and insight into disease mechanisms.
- Treatment decisions, including the choice of antithrombotics and revascularization strategy, should be individualized based on patient risk.
Abstract:
Recent clinical trial evidence supports an inflammatory etiology in acute ischemic heart disease. When a segment of coronary artery becomes inflamed, important cytokines, such as tissue factor, are released, facilitating thrombosis. Serum inflammatory markers are elevated in most acute coronary syndrome patients at presentation. Mortality risk has been shown to be associated with increased levels of high-sensitivity C-reactive protein (CRP), interleukin 6, and serum vascular cell adhesion molecule. Platelets, which are rich in inflammatory mediators (CD40 and its ligand thrombospondin, and phospholipase A2), also supply important triggers for the inflammatory cascade. In addition, more than 35 platelet-associated messenger ribonucleic acid mediators involved in arterial injury and inflammation have been found. The use of biomarkers of inflammation, such as CRP, and of the sequelae of embolization, such as troponin, provide a window into the underlying pathophysiology of acute ischemic heart disease. New agents from three distinct drug classes have recently flooded the therapeutic armamentarium. Decision-making is further complicated by the choice of an invasive (aggressive) or a medical (conservative) strategy of management with respect to coronary revascularization. For patients at highest risk, aspirin, beta-blockers, nitrates, and a statin should be given, and clopidogrel, enoxaparin, a glycoprotein (GP) IIb/IIIa inhibitor, plus an invasive strategy should be considered. For intermediate- and low-risk patients, a "sliding-scale" approach may be best. Decisions about the three classes of antithrombotics--low-molecular-weight heparins, GP IIb/IIIa inhibitors, and thienopyridines--along with whether to adopt an early invasive strategy, should be made on an individual basis.